Peptide-MHC tetramer staining showed that significantly higher percentages(10.87% ± 0.3786 and 2.797% ± 0.6067) of Mapkbp1 specific CD8+ T cells were observed in PBMCs and TILs from mice treated with combined therapy compared to other treated mice (PBS: 0.8033% ± 0.3225 and 0.61% ± 0.2227; LLCvac: 6.850% ± 0.4618 and 1.707% ± 0.157; Bev + anti-PD-1:0.7467% ± 0.1002 and 1.173% ± 0.157, respectively), suggesting the strong neoantigen-specific T-cell infiltration into the tumor by the combined therapy. Here, MAPKBP1 is linked to neoplasm.